Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300719 | 0.85 | ALDH1A1 (0.67) | LMNAALDH1A1KDM4EMEN1GAA | |
| SCHEMBL8512850 | 0.84 | MEN1 (0.56) | LMNAALDH1A1KDM4EMEN1GAA | |
| SCHEMBL8515925 | 0.82 | ALOX5 (0.64) | LMNAALDH1A1KDM4EMEN1GAA | |
| SCHEMBL3888738 | 0.81 | AR (0.59) | ARLMNAALDH1A1KDM4EMEN1 | |
| SCHEMBL16585681 | 0.79 | CTSV (0.57) | LMNAMEN1GAAMAPTKMT2A | |
| SCHEMBL8512448 | 0.79 | KMT2A (0.50) | LMNAALDH1A1KDM4EMEN1GAA | |
| SCHEMBL19846945 | 0.78 | KDM4E (0.58) | LMNAALDH1A1KDM4EMEN1GAA | |
| SCHEMBL28023307 | 0.76 | LMNA (0.55) | ARLMNAALDH1A1KDM4EMEN1 | |
| SCHEMBL30482846 | 0.76 | ALDH1A1 (0.76) | LMNAALDH1A1KDM4EMEN1GAA | |
| SCHEMBL8512623 | 0.75 | NPC1 (0.47) | LMNAALDH1A1KDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674906-B2 | Tetracyclic immunomodulatory compounds | ACTIVE BIOTECH AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-7674906-B2 | Tetracyclic immunomodulatory compounds | ACTIVE BIOTECH AB (SE) | 2010-03-09 | — | — | US | disclosed |
| EP-1572689-B1 | TETRACYCLIC IMMUNOMODULATORY COMPOUNDS | ACTIVE BIOTECH AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| US-20060035919-A1 | Tetracylic immunomodulatory compounds | ACTIVE BIOTECH AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035919-A1 | Tetracylic immunomodulatory compounds | ICOS, CD74, CD40 | AR 2095/4885LMNA 4710/4885ALDH1A1 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.